Multiple sclerosis, 2000-02, Vol.6 (1), p.56-58
2000
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors
- Ist Teil von
- Multiple sclerosis, 2000-02, Vol.6 (1), p.56-58
- Ort / Verlag
- Thousand Oaks, CA: SAGE Publications
- Erscheinungsjahr
- 2000
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Phosphodiesterase inhibitors (PDEIs), when used in combination, synergistically suppress TNFa production by various cells and also suppress experimental demyelination at very low concentrations. We conducted a pilot study to determine whether the combination of three PDEIs suppresses the relapse of MS at the usual therapeutic doses. Of the 12 relapsing remitting MS, the mean relapse rate/year dropped remarkably (from 3.08+3.32 to 0.92+1.86) after PDEI treatment. Seven out of 12 (58.3%) were relapse-free in the follow up period (499+142 days). The combination of three PDEIs can be safe and useful strategy for the future treatment of MS.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1352-4585eISSN: 1477-0970DOI: 10.1177/135245850000600111Titel-ID: cdi_proquest_miscellaneous_70945376
- Format
- –
- Schlagworte
- Adult, Biological and medical sciences, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Medical sciences, Middle Aged, Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis, Multiple Sclerosis, Relapsing-Remitting - drug therapy, Multiple Sclerosis, Relapsing-Remitting - metabolism, Neurology, Neuroprotective Agents - administration & dosage, phosphodiesterase inhibitors, Phosphodiesterase Inhibitors - administration & dosage, Pilot Projects, Recurrence, Theophylline - administration & dosage, Treatment Outcome, tumor necrosis factor-^a, Tumor Necrosis Factor-alpha - metabolism, Vinca Alkaloids - administration & dosage, Xanthines - administration & dosage